| Identification | Back Directory | [Name]
(R)-5-(3-chlorophenyl)-3-(1-((4-Methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)oxy)ethyl)isoxazole | [CAS]
934282-55-0 | [Synonyms]
AZD2066)
AZD 2066
(AZD-2066
4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine
Pyridine, 4-[5-[(1R)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]-
(R)-5-(3-chlorophenyl)-3-(1-((4-Methyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)oxy)ethyl)isoxazole | [Molecular Formula]
C19H16ClN5O2 | [MDL Number]
MFCD22420281 | [MOL File]
934282-55-0.mol | [Molecular Weight]
381.82 |
| Chemical Properties | Back Directory | [Melting point ]
140-142°C | [Boiling point ]
626.3±65.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
1.91±0.10(Predicted) | [color ]
White to Off-White | [InChI]
1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1 | [InChIKey]
SXWHYTICXCLKDG-GFCCVEGCSA-N | [SMILES]
Clc1cc(ccc1)c2[o]nc(c2)[C@H](Oc3[n](c(nn3)c4ccncc4)C)C |
| Hazard Information | Back Directory | [Uses]
AZD 2066 is a mGluR5 anatagonist that is used for treating and preventing pain, neurological, psychiatric and other diseases. | [Biological Activity]
AZD2066 is an orally bioavailablebrain penetrantselective and potent negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5). AZD2066 exhibited satisfactory efficacy in patients suffering from neuropathic pain with mechanical hypersensitivity. | [in vivo]
AZD 2066 (0.3-30 mg/kg, p.o., 60 min) shows discriminative effects in rats[2].
AZD-2066 (10 μM, perfusion of brain slide) alleviates dihydroxyphenylglycine (DHPG)-facilitated long-term depression (LTD) expression in chronic social defeat stress (CSDS)-treated mice via BDNF/trkB signaling pathway[5].
AZD-2066 (5 mg/kg, i.p., 2 × 12 h) alleviates chronic social defeat stress (CSDS)-induced depressive behaviors in mice[5].
| Animal Model: | Male Wistar rats (weighing 240-250 g)[2] | | Dosage: | 0.03, 0.1, 0.3, 1, 3, 10, 30 mg/kg | | Administration: | Oral gavage (p.o.) | | Result: | Caused full and dose-dependent AZD9272-appropriate responding.
|
| Animal Model: | Depressive model (C57BL/6 mice were subjected to physical defeats that were generated by a CD-1 aggressor for 5 min every day for 10 days)[5] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection (i.p.), 2 × 12 h | | Result: | Increased social interaction ratio.
Reversed time spent in interaction zone.
Increased sucrose preference scores.
|
| [IC 50]
mGluR5 | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|